Abstract Accumulating evidence has suggested resveratrol as a promising drug candidate for the treatment of epilepsy. To validate this, we tested the protective effect of resveratrol on a kainic acid (KA)-induced epilepsy model in rats and investigated the underlying mechanism. We found that acute resveratrol application partially inhibited evoked epileptiform discharges in the hippocampal CA1 region. During acute, silent and chronic phases of epilepsy, the expression of hippocampal kainate glutamate receptor (GluK2) and the GABA A receptor alpha1 subunit (GABA A R-alpha1) was up-regulated and down-regulated, respectively. Resveratrol reversed these effects and induced an antiepileptic effect. Furthermore, in the chronic phase, resveratrol treatment inhibited the KA-induced increased glutamate/GABA ratio in the hippocampus. The antiepileptic effects of resveratrol may be partially attributed to the reduction of glutamate-induced excitotoxicity and the enhancement in GABAergic inhibition.
Introduction
Epilepsy is a serious neurological disorder marked by recurrent seizures, affecting *50 million people worldwide [1] . Temporal lobe epilepsy (TLE) is the major form of acquired epilepsy in adults, involving seizures that often arise in the mesial temporal lobe of the hippocampus [2] . Several animal models have been developed to explore the epileptogenic mechanisms, and kainic acid (KA, also known as kainate) is widely used to induce animal models to investigate TLE [3, 4] . Despite these studies, the causes of epilepsy are still not fully understood, and few neuroprotectants have been successfully translated from the laboratory to clinical practice.
Resveratrol (3, 4, 5-trihydroxy-trans-stilbene) is a natural product found in grape skin, cranberries, peanuts, and other plants. Red wine is considered to be its most important dietary source [5] . Pharmacological studies have revealed that it influences a variety of biological processes, including antioxidant [6] , anti-inflammatory [7] , and antiageing pathways [8] . In the central nervous system, resveratrol has been shown to have neuroprotective effects against cerebral stroke [9] and KA-induced epilepsy [10] . We previously showed that chronic resveratrol treatment effectively protects the brain against focal cerebral injury [11] , KA-induced seizures and neurotoxicity [12, 13] , and down-regulates hippocampal KA receptor expression in rats [13] . In this study, we further evaluated its protective effects against a KA-induced model of TLE.
Glutamate (Glu) is a major excitatory transmitter in the brain, and KA can cause prolonged depolarization and even neuronal death via Glu receptors [14] . Presynaptic KA receptors regulate Glu or c-aminobutyric acid (GABA) release [15] , indicating their important role in the etiology of epilepsy. Epilepsy is associated with an excitatory/ inhibitory imbalance in the underlying neuronal network [16] . For this reason, we speculated that down-regulation of inhibitory synaptic inputs to neurons precipitates in epileptic activity. KA-induced epileptogenesis is mediated partially by GluK2-containing postsynaptic KA receptors located on mossy-fiber synapses distributed extensively on CA3 pyramidal cells [17] . Epileptogenesis has also been correlated with profound changes in GABA A receptor subunits, predominantly the alpha-1 subunit [18] .
In the present study, we developed a TLE model by injecting KA into the core of the right hippocampal CA3 region to evaluate the epileptogenesis and progression of TLE and analyze the mechanism underlying the antiepileptic effects of resveratrol. The effects of resveratrol on the expression of GluK2 and GABA receptor alpha-1 (GABAR-a1) in various phases of TLE and its influence on the ratio of Glu to GABA in the hippocampus of KA-induced rats were investigated.
Material and Methods

Animals
All animal studies were conducted at the Animal Facility at Anhui Medical University approved by the Association for Assessment and Accreditation of Laboratory Animal Care International. Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals (8th Edn). All experimental protocols were approved by the Animal Care and Use Committee of Anhui Medical University. All efforts were made to minimize animal suffering and reduce the number of animals used. Male Wistar rats (200-250 g) were housed in a temperaturecontrolled (25°C) room under a 12:12 light/dark cycle with lights on at 07:00. The animals had free access to food and water.
Rat Model of Temporal Lobe Epilepsy
Rats were anesthetized with a mixture of 70% nitrous oxide, 30% oxygen, and 1.5% halothane for surgery. A bolus of 2.5 lL KA (0.4 lg/lL) was injected slowly (during *15 min) into the CA3 region of the right hippocampus (4.0 mm posterior to bregma, 4.4 mm lateral to midline, 3.8 mm below dura), after which the animal was held in place for 10 min. The KA-induced seizures were rated according to Racine's standard classification: 0, normal; 1, stereotyped mounting, eye-blinking, and/or mild facial clonus; 2, head-nodding and/or several episodes of facial clonus; 3, myoclonic jerks in forelimbs; 4, clonic convulsions in forelimbs with rearing; and 5, generalized clonic convulsions associated with loss of balance [19] . Only rats that reached class 4 or above were used as successful models in the subsequent experiments, and were divided into three groups: the control, KA, and KA ? Res (resveratrol) groups. Controls received an equivalent volume of saline injected into the same site. All rats in the chronic experiments were divided according to the various phases of TLE: the acute (3 days after initial status epilepticus), silent (14 days after initial status epilepticus), and chronic phases (60 days after initial status epilepticus). The KA ? Res group received resveratrol intragastrically at 15 mg/kg. During the acute phase, resveratrol was administered once per day for three days after the onset of seizures. During the silent and chronic phases, resveratrol dissolved in 40% propylene glycol was administered for 10 consecutive days after initial seizure onset. The control and KA-treated rats received vehicle (40% propylene glycol in saline).
Behavioral Monitoring
After KA injection, rats were allowed free access to standard dry rat diet and tap water and were maintained under standard laboratory conditions (23 ± 1°C) with a natural light/dark cycle. Spontaneous seizures were monitored on a video-capture system for 8 h/day, 5 days/week.
Electrophysiological Analysis
Extracellular recording was conducted two weeks after the induction of epilepsy. Immediately after deep anesthesia with ethyl ether, the brain was harvested and placed into ice-cold artificial cerebrospinal fluid (ACSF) for *2 min. The ACSF (in mmol/L: NaCl 128, KCl 1.7, KH 2 PO 4 1.24, MgSO 4 1.3, CaCl 2 2.4, NaHCO 3 26.0, and glucose 10.0) was oxygenated with a mixture of 95% O 2 and 5% CO 2 at a pH adjusted to 7.4. Coronal slices (400 lm thick) were cut on a manual vibratome (Microslicer DTK 1500, Dousaka EM Co., Kyoto, Japan) and immediately transferred to a submerged holding chamber containing ACSF at room temperature for at least 1 h for recovery. A single slice was transferred to a recording chamber mounted on a vibration isolation table, continuously perfused with oxygenated ACSF at 1-2 mL/min at *32°C, and viewed through an inverted microscope (IMT-2, Olympus, Tokyo, Japan). Orthodromic stimuli were delivered by a bipolar tungsten electrode placed in the stratum radiatum near the border between CA1 and CA2, targeting the Schaffer collateral/commissural pathway. Population spikes (PSs) were recorded in the CA1 pyramidal cell layer with a 3-8 MX resistance glass microelectrode filled with 2 mol/L NaCl solution.
Western Blot Analysis
Rats were sacrificed with an overdose of chloral hydrate, and the brain immediately harvested. The hippocampus on both sides were removed and stored at -80°C until use. Total protein was isolated from the whole hippocampus of each rat and its concentration determined using a BCA Protein Assay kit (Pierce, Rochford, IL). After separation on a 10% resolving gel, proteins were transferred to a BioTrace PVDF membrane. The membrane was blocked with 5% nonfat dry milk in PBS for 1 h at room temperature followed by incubation with rabbit anti-KA receptor GluK2 (1:1000) or rabbit anti-GABA A R-a1 (1:1000) primary antibody diluted in blocking buffer. After three washes with PBS-0.05% Tween 20 (PBS-T), membranes were incubated with the secondary antibody and HRPconjuncted antibody for GAPDH for 90 min at room temperature. Protein bands were visualized using an ECL Detection Kit (Amersham Biosciences, Piscataway, NJ). Membranes were washed with 100 mmol/L 2-mercaptoethanol, 2% SDS, and 62.5 mmol/L Tris-HCl (pH 6.7) at 50°C for 30 min and re-incubated with an antibody targeting a separate protein. All blots were digitized and quantified using NIH ImageJ software (National Institutes of Health, Bethesda, MD).
High-Performance Liquid Chromatography (HPLC)
Rats were deeply anesthetized with chloral hydrate (350 mg/kg, i.p.) and decapitated. The right hippocampus was immediately dissected on ice, homogenized in 1 mL saline (25,000 rpm for 10 s) and then centrifuged at 4°C (12,000 rpm for 20 min) to obtain the supernatant (1 mL). Acetonitrile (3 mL) was added to the supernatant to remove protein by centrifuging at 4°C (12,000 rpm for 10 min). An amino-acid standard solution or the diluted sample was evaluated using pre-column derivatization with phenyl isothiocyanate solution before chromatographic analysis.
The concentrations of Glu and GABA in the hippocampus were determined by calculating the peak areas and standard curves. Microdialysates were separated by HPLC (Agilent 1100 LC/MSD) using a Venusil AA column (250 mm long, 4.6 mm in diameter, and 5 lm pore size) and analyzed with an ultraviolet detector (wavelength, 254 nm). The mobile phase contained 50 nmol/L sodium acetate (pH 5.5), deionized water (HPLC grade), methanol, and 5% (v/v) tetrahydrofuran at a flow rate of 1.0 mL/min. The column temperature was set at 40°C and a linear, graded protocol in solvent B (methyl cyanide) was carried out as follows: 0% to 10% solvent for 20 min, followed by 10% to 18% for 10 min, 18% to 30%, and then 100% for the final 10 min.
Reagents
Resveratrol, KA, bicuculline, and protease inhibitor cocktail were from Sigma (St. Louis, MO). Rabbit anti-GluK2 affinity-purified polyclonal antibody and rabbit anti-GABA A R-a1 affinity-purified polyclonal antibody were from Chemicon (Temecula, CA). Other chemicals of special grade were from Wako (Osaka, Japan).
Data Analysis
All data were analyzed with SPSS 16.0 (IBM Inc., Chicago, IL) and are expressed as mean ± SEM. Differences in PS amplitude between groups were analyzed using Student's t-test. Differences among groups were analyzed using two-way ANOVA followed by LSD multiple comparison if significance was found. A P value \0.05 was considered statistically significant.
Results
Effect of Resveratrol on KA-Induced Epilepsy Behavior
The numbers of rats reaching at least class 4 were 0/8 in the control, 7/8 in the KA, and 6/8 in the KA ? Res groups. There was no difference in the rate of seizures between the KA and KA ? Res groups in the acute phase (87.5 ± 3.7% vs 75.0 ± 3.2%, P [ 0.05). No rats developed spontaneous seizures in any of the three groups in the silent phase. However, the rate of spontaneous seizures was markedly lower in the KA ? Res group than in the KA group in the chronic phase (87.5 ± 3.7% vs 12.5 ± 2.3%, P \ 0.05).
Resveratrol Did Not Change the Population Spike Amplitude in Hippocampal CA1 of Control Rats
Extracellular field PSs were recorded in the stratum pyramidale during Shaffer collateral-CA1 synaptic transmission. In the control group, a single PS was recorded in the pyramidal cell layer of the CA1 region (Fig. 1A) . To test the effect of various concentrations on PS amplitude, we perfused 5, 15, and 50 lmol/L resveratrol directly onto hippocampal slices from the control group for 20 min. The amplitude of the PS was not affected by these concentrations ( Fig. 1B; original PSs in Fig. S1 ). These results showed that resveratrol itself has no effect on PS amplitude at the concentrations used.
Effect of Resveratrol on Epileptiform Activity in Rat Hippocampal Slices
Since the hippocampus is susceptible to epileptiform activity [20] , we evaluated the effect of epilepsy on PSs in the CA1 region. In slices from rats with KA-induced TLE, a stimulus applied to the pyramidal cell layer evoked epileptiform discharges that consisted of 3-6 PSs ( Fig. 2A) . This indicated that KA injection into the hippocampus can evoke epileptiform activity. Li et al. demonstrated that resveratrol inhibits neuronal discharges in the rat hippocampal CA1 area in a dose-dependent Fig. 1 Resveratrol has no effect on the amplitude of population spikes in the control group. A A single PS in the hippocampal CA1 pyramidal cell layer of a control rat (arrow, stimulus artifact). B Acute application of resveratrol (5, 15, and 50 lmol/ L) to hippocampal slices from the control group did not alter the PS amplitude (8 slices from 3 rats, P [0.05).
Fig. 2
Epileptiform discharges are evoked in the hippocampal CA1 region of rat models of TLE induced by KA. A Typical multiple peaks of PS epileptiform discharges recorded in a hippocampal slice from a rat with KA-induced TLE. B After acute perfusion with resveratrol (Res; 5 lmol/L) for 20 min, the amplitudes of the first 4 PS peaks and the total number of PS peaks were not affected (6 slices from 4 rats, P [0.05). C The amplitudes of the first 4 PS peaks and the total number of PS peaks were not affected by perfusion with 15 lmol/L Res for 20 min (6 slices from 4 rats, P [0.05). D After perfusion with 50 lmol/L Res for 20 min, the amplitudes of the first 4 PS peaks were clearly decreased (6 slices from 5 rats, **P\0.01). E When slices from the control group were perfused with 50 lmol/L Res for 20 min, the amplitudes of the PS peaks were clearly decreased (6 slices from 5 rats, **P \0.01).
manner [21] . Similarly, we found that perfusion with 5 and 15 lmol/L resveratrol for 20 min did not affect the amplitudes of the first 4 PS peaks and the total number of PS peaks (Fig. 2B and C) . However, perfusion with 50 lmol/L resveratrol for 20 min reversibly decreased the amplitudes of the first 4 PS peaks and the total number of PS peaks ( Fig. 2D and E; original PSs in Fig. S2 ). This suggests that resveratrol at 50 lmol/L partially inhibits the epileptiform discharges evoked in this region.
The total number of PSs during epileptiform discharges is correlated with the intensity of the test stimulus [22] , while a conditioning stimulus typically fails to activate the GABA A R-mediated inhibitory pathway [23] . Here, we found that a repetitive pattern of PS epileptiform discharges was induced by perfusing ACSF with bicuculline (30 lmol/L), a GABA A R antagonist, into control hippocampal slices (Fig. 3A) . These results showed that under normal physiological conditions, GABAergic inhibition may contribute to inhibiting excitatory neurotransmission and therefore plays a role in combating epileptogenesis. The amplitudes of the first 4 PS peaks and the total number of PS peaks were not significantly affected by perfusion with ACSF with 5 or 15 lmol/L resveratrol for 20 min (Fig. 3B and C) . However, 50 lmol/L resveratrol perfused for 20 min decreased the amplitudes of the first 4 PS peaks and the total number of PS peaks ( Fig. 3D and E ; original population spikes in Fig. S3 ).
Effects of Resveratrol on the Expression of GluK2 and GABA Receptor-Alpha 1 in Different Phases of Epilepsy
Gao et al. reported that resveratrol reversibly inhibits excitatory synaptic transmission via suppression of Gluinduced current in CA1 pyramidal neurons [24] . In the acute phase, we found that the expression of GluK2 and GABA A R-a1 in hippocampal neurons were lower in the KA group than in controls. Furthermore, compared with the KA group, resveratrol treatment up-regulated the expression of GluK2 and GABA A R-a1 (Fig. 4) , indicating that it restores the expression of GluK2 and GABA A R-a1 in this phase of KA-induced epilepsy. In the silent phase, hippocampal GluK2 and GABA A R-a1 were barely detectable in the KA group. However, resveratrol increased the expression of GluK2 and GABA A R-a1 compared with the KA group. In the chronic phase, expression of GluK2 and GABA A R-a1 was significantly higher in the KA group than in the control group. GABA A R-a1 was found to be higher while GluK2 was lower in the KA ? Res group than in the KA group (Fig. 4) .
Effect of Resveratrol on Amino-Acid Levels in Different Phases of Epilepsy
The results of HPLC showed that in the acute phase, the Glu/GABA ratio in the hippocampus was higher in the KA and KA ? Res groups than in the control group. Resveratrol did not inhibit the epilepsy-induced elevation in the Glu/ GABA ratio. In the silent phase, there was no significant difference in the Glu/GABA ratio among the three groups. In the chronic phase, the ratio was higher in the KA group than in the control group, and lower in the KA ? Res group than in the KA group (Table 1) . These results suggest that resveratrol prevents the imbalance between excitatory and inhibitory amino-acid neurotransmitters in the rat hippocampus during KA-induced seizures. The neuroprotective effect of resveratrol indicates that it is capable of blocking the excitotoxic effects of glutamate in the hippocampus in the chronic phase of KA-induced epilepsy.
Discussion
Epilepsy is one of the most common neurological disorders. As described previously, epileptic seizures may result from an imbalance between excitatory and inhibitory neurotransmitters [25] . Other studies have demonstrated that the hippocampal concentrations of amino-acids are affected by epilepsy [26, 27] . We confirmed these findings, indicating that the GABA A and Glu receptors play important roles in the development of seizures in a model of TLE. Resveratrol demonstrated neuroprotective properties against KA-induced epilepsy. Furthermore, our data showed that the antiepileptic effects of resveratrol in the hippocampus may be associated with maintenance of the Glu/GABA ratio.
The hippocampus is vulnerable to epilepsy-induced injury, especially in the CA1 region [20] . One of our previous studies revealed that resveratrol markedly protects against KA-induced neuronal death in both the CA1 and CA3 regions in a TLE model [13] . Glial proliferation is involved in the pathogenesis of the human hippocampus in TLE, and resveratrol treatment suppresses the KA-induced activation of astrocytes and microglial cells [28] . In the present study, we found that a test stimulus was able to evoke bursts of repetitive PSs in the CA1 region in KAinduced TLE model rats, and acute perfusion with 50 lmol/L resveratrol reduced these epileptiform discharges. From these data, we speculated that resveratrol inhibits the electrical activity of hippocampal pyramidal neurons. We used bicuculline to block a large portion of GABA A Rmediated inhibition in hippocampal pyramidal cells. Acute perfusion with 50 lmol/L resveratrol reduced the bicuculline-evoked epileptiform activity in the CA1 region. Similarly, Wan et al. demonstrated that cyclothiazide-induced epileptiform activity in CA1 neurons is suppressed by the activation of extrasynaptic GABA A Rs [29] . Together, these results further suggest that the GABA A R plays a prominent role in seizure generation, and resveratrol inhibits the electrical activity of hippocampal pyramidal neurons by enhancing GABAergic synaptic inhibition.
Feedback regulation is common in information processing by neuronal circuits [30, 31] . KA receptors play a key role in the regulation of synaptic network activity [32, 33] . Liu et al. showed that the activation of KA-type receptors leads to anxiety-related behaviors and the upregulation of glutamatergic synapses [34] . In our study, resveratrol alone had no apparent effect on postsynaptic Glu receptors (Fig. 1) . Compared to normal rats, chronic resveratrol treatment causes no observable change in rat CA1 pyramidal neurons and does not alter the expression of Bcl-2 and Bax [11] . Much evidence suggests that the neuronal damage induced by KA in the hippocampal region is followed by neuronal hyperexcitability due to the lack of a tonic GABA A R effect in the acute phase [35, 36] . It has been reported that resveratrol increases Glu uptake [37] . Consistent with these results, we found that GluK2 and GABA A R-a1 expression decreased and the Glu/GABA ratio increased in the hippocampus during the acute phase of KA-induced epilepsy. Resveratrol increased the expression of both GluK2 and GABA A R-a1 without affecting the imbalance between excitatory and inhibitory amino-acids in the hippocampus. The inability of resveratrol to inhibit epileptic seizures in the acute phase may be due to increased KA receptor density in the hippocampus [38] .
The silent phase is regarded as a characteristic interval in the time-dependent epileptogenic processes. Several studies have shown that GABAergic activity is suppressed during this period [39, 40] . Our results showed that the expression of GluK2 and GABA A R-a1 in the hippocampus was almost undetectable during the silent phase in the KA group and that resveratrol increased the expression of GABA A R-a1. This effect might be partly due to resveratrol causing an increased accumulation of GABA in an attempt to control brain excitability [41] . We speculate that there may be a temporal balance of the Glu/GABA ratio in the silent phase. In the chronic phase, the expression of GluK2 and GABA A R-a1 was significantly increased in the KA group, and resveratrol down-regulated GluK2 and increased the expression of GABA A R-a1. Meanwhile, resveratrol significantly decreased the Glu/GABA ratio in the hippocampus. This evidence supports our hypothesis that the antiepileptic effects of resveratrol are closely correlated with its suppression of Glu excitation and enhancement of the inhibitory effect of GABA, yet the detailed mechanism of this process remains unclear. Further investigations are needed to better understand the precise role of resveratrol in the up-regulation of GluK2 and GABA A R-a1 compared to the KA group.
